Epidemiology, Sociodemographic Characteristics, Symptoms Assessment and Outcome of COVID-19 Epidemic among Residents of Niger State, Nigeria (March 2020 – March 2021)
Main Article Content
Abstract
Nigeria recorded the first case of COVID-19 infection on Feb 27, 2020. Thereafter, National response was imposed with different curtailing measures including travel bans, closure of schools, markets and limiting the number of persons that could congregate in a place. The objective of this study was to evaluate the epidemiological situation of COVID-19 in Niger state, Nigeria using the data collected during the outbreak, describing the sociodemographic characteristics and epidemiological behavior and clinical symptoms of those tested and confirmed COVID-19 cases. We conducted a state wide population based analysis of the epidemiology of COVID-19 using data reported from all the 25 Local Government Areas of the state from March 2020 to March 2021 for the first, second and third waves of the epidemic. We calculated the overall incidence, case fatality rate, association of sociodemographic variables and the outcome of COVID-19 cases, frequency of different symptoms and drew an epidemic curve. A total of 1128 cases and 20 deaths were included in the analysis with sex distribution of 63.9% males and 36.1% females. The overall incidence rate was 20 cases per 100,000 populations. Commonest symptoms were cough (62.5%), Fever (54.2%) and difficulty in breathing (42%). We found that age was an important determinant of death in COVID-19 cases and health care workers were significant contributors of morbidity and mortality. We recommend strengthening of the health care system especially emergency response, availability of intensive care services, improvement of laboratory services, community surveillance and contact tracing capacities to prevent and control future epidemics.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020; 1;49(3):717-726. https://doi.org/10.1093/ije/dyaa033 PMID: 32086938
II. Ortiz-Prado E, Simbaña-Rivera K, Go´mez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, et al. Clinical, molecular and epidemiological characterization of the SARS-CoV2 virus and the Coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020; 98(1):115094. https://doi.org/10.1016/j.diagmicrobio.2020.115094 PMID: 32623267
III. Gilbert M, Pullano G, Pinotti F, Valdano E, Poletto C, Boe¨lle P-Y, et al. Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. The Lancet. 2020; 395: 871– 877. https://doi.org/10.1016/S0140-6736(20)30411-6 PMID: 32087820
IV. Worldometer, COVID 19 Coronavirus Pandemic, (2021) https://www.worldometers.info/coronavirus/ retrieved on the 2nd October 202
V. Ortiz-Prado E, Simbaña-Rivera K, Go´mez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, et al. Clinical, molecular and epidemiological characterization of the SARS-CoV2 virus and the Coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020; 2020; 98(1):115094. https://doi.org/10.1016/j.diagmicrobio.2020.115094 PMID: 32623267
VI. Bernard K. COVID-19 in Nigeria: a disease of hunger, Lancet Respir Med. 2020; 8(6): 556–557.
VII. Published online 2020 Apr 29. doi: 10.1016/S2213-2600(20)30220-4
VIII. Adegboye OA, Adekunle AI, Gayawan E. Early Transmission Dynamics of Novel Coronavirus (COVID-19) in Nigeria. International Journal of Environmental Research and Public Health. 2020; 17(9):3054. https://doi.org/10.3390/ijerph17093054
IX. Amzat J, Aminu K, Kolo VI, Akinyele AA, Ogundairo JA, Danjibo MC. Coronavirus outbreak in Nigeria: Burden and socio-medical response during the first 100 days. Int J Infect Dis. 2020; 98:218-224.
doi: 10.1016/j.ijid.2020.06.067
X. Majiya H. Aliyu-Paiko M., Balogu V.T, Musa D.A., Salihu I.M., Kawu A.A, Seroprevalence of COVID-19 in Niger State, 2020:
https://www.medrxiv.org/content/10.1101/2020.08.04.20168112v1.full.pdf
XI. Byambasuren O, Dobler CC, Bell K, Rojas DP, Clark J, et al, Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review. PLOS ONE, 2021; 16(4):
e0248946. https://doi.org/10.1371/journal.pone.0248946
XII. Laia C.C, Wanga J.H, Hsueh P.R [2020] Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review, International Journal of Infectious Diseases 101, 2020; 314–322
XIII. NCDC, COVID 19 Nigeria, 2021; Accessed at https://covid19.ncdc.gov.ng/ on the 22nd November 2021
XIV. NCDC, Public health advisory on COVID 19, 2021; Accessed at https://covid19.ncdc.gov.ng/advisory/ on the 22nd of November 2021.
XV. Niger State Government, About Niger state: ministry of science and technology Minna, Niger state, 2017.
XVI. National Bureau of Statistics [NBS], Demographic statistics bulletin: National Bureau of statistics 2017
XVII. Niger State Government, About Niger state: transforming Education in Niger state (tens), (2021); Accessed at http://tens-niger.com/about-tens/about-niger-state/
XVIII. Jassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, et.al, Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. Lancet HIV. 2021; 8(9): e554-e567. doi: 10.1016/S2352-3018(21)00151-X. Epub 2021 Aug 4. PMID: 34363789; PMCID: PMC8336996
XIX. 20. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720
XX. 21. Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. Jama. 2020; 323: 1335–1335. https://doi.org/10.1001/jama.2020.4344 PMID: 3218179522. NBS, Demographic statistics bulletin, Demographic Statistics Bulletin 2017.pdf
XXI. 23. Statista, Age distribution of population in Nigeria in 2021, by gender, 2021; https://www.statista.com/statistics/1121317/age-distribution-of-population-in-nigeria-by-gender
Retrieved on 11th December 2022
XXII. Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in case fatality rates (CFR) of COVID19/SARS-COV-2 in Italy and China. J Infect Dev Ctries. 2020; 14: 125–128. https://doi.org/10.3855/jidc. 12600 PMID: 32146445
XXIII. Forte F. Spain: coronavirus mortality rate by age, In: Statista [Internet], 2020; Available from: https://www.statista.com/statistics/1105596/covid-19-mortality-rate-by-age-group-in spain-march/ Retrieved 11 December 2022
XXIV. Hu D, Lou X, Meng N, Li Z, Teng Y, Zou Y, Wang F, Influence of age and gender on the epidemic of COVID-19: Evidence from 177 countries and territories-an exploratory, ecological study. Wien Klin Wochenschr. 2021; 133(7-8):321-330
XXV. Leidman E, Duca LD, Omura JD, Proia K, Stephens JW, Sauber-Schatz EK, COVID-19 Trends Among Persons Aged 0–24 Years — United States, March 1–December 12, 2020, MMWR, 2021 / 70(3);88–94
XXVI. CDC, Risk for COVID-19 Infection, Hospitalization, and Death by Age Group, 2022; https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.htm Retrieved 11th December 2022
XXVII. Alasia D D, Maduka O, Prevalence and Pattern of COVID-19 among Healthcare Workers in Rivers State Nigeria, Occupational Diseases and Environmental Medicine, 2021;Vol.9 No.1
XXVIII. Shahriarirad, R., Khodamoradi, Z., Erfani, A., Hosseinpour, H., Ranjbar, K., Emami, Y., Mirahmadizadeh, A., et al., Epidemiological and Clinical Features of 2019 Novel Coronavirus Diseases (COVID-19) in the South of Iran. BMC Infectious Diseases, 2020; 20, 427.
XXIX. Giesen, C., Diez-Izquierdoa, L., Saa-Requejoa, C.M., Lopez-Carrilloa, I., Lopez-Vilelaa, C.A., Seco-Martineza, A. and Prieto, M.T.R., Epidemiological Characteristics of the COVID-19 Outbreak in a Secondary Hospital in Spain. American Journal of Infection Control, 2020; 49, 143-150.
XXX. Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020; 61(3): E304-E312.
XXXI. Ortiz-Prado E, Simbaña-Rivera K, Barreno LG, Diaz AM, Barreto A, Moyano C, et al., Epidemiological, socio-demographic and clinical features of the early phase of the COVID-19 epidemic in Ecuador. PLoS Negl Trop Dis, 2021; 15(1): e0008958.
XXXII. Vaira LA, Salzano G, Deiana G, De Riu G, Anosmia and ageusia: common findings in COVID-19 patients. The Laryngoscope. 2020; 130(7):1787
XXXIII. Odukoya OO, Adejimi AA, Isikekpei B, Jim CS, Osibogun A, Ogunsola FT. Epidemiological trends of coronavirus disease 2019 in Nigeria: From 1 to 10,000. Niger Postgrad Med J. 2020; 27(4):271-279
XXXIV. Jang, S.Y., Hussain-Alkhateeb, L., Rivera Ramirez, T. et al., Factors shaping the COVID-19 epidemic curve: a multi-country analysis. BMC Infect Dis, 2021; 21:1032